Plasma levels of selected GVHD biomarkers IL-2R (CD25), IL-33R (suppression of tumorigenicity 2), KRT 18, HGF, CD30, TNR-R1, and granzyme A measured at baseline (pretreatment) and day 14. ∗P < .05; ∗∗P < .01. HGF, hepatocyte growth factor; TNF-R1, tumor necrosis factor receptor 1.